Based on the results obtained in clinical trials, primarily the phase 3 HOPE trial, voxelotor has demonstrated efficacy in increasing Hb levels and decreasing hemolytic markers in patients with SCD. This evidence concerns the gene GSTM1 and Schnyder corneal dystrophy.